###begin article-title 0
TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration
###end article-title 0
###begin p 1
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 111 119 <span type="species:ncbi:9606">patients</span>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
###xml 456 464 <span type="species:ncbi:9606">patients</span>
###xml 527 535 <span type="species:ncbi:9606">patients</span>
###xml 600 608 <span type="species:ncbi:9606">patients</span>
Autopsy studies have shown that about 55% of patients with frontotemporal lobar degeneration (FTLD) and 25% of patients with Alzheimer's disease (AD) harbour TDP-43 immunoreactive pathological changes in their brains. Using ELISA, we investigated whether we could detect the presence, or increased amounts, of TDP-43 in plasma of patients with FTLD and AD compared to normal control subjects. We detected elevated levels of TDP-43 protein in plasma of 46% patients with FTLD with clinical frontotemporal dementia (FTD) and 22% patients with AD, compared to 8% of control subjects. The proportions of patients with FTD and AD showing raised plasma TDP-43 levels correspond closely to those proportions known from autopsy studies to contain TDP-43 pathological changes in their brains. Raised TDP-43 plasma levels may thereby index TDP-43 pathology within the brain. Plasma TDP-43 levels may be a biomarker that can provide a laboratory test capable of identifying the presence of TDP-43 brain pathology in neurodegenerative disease during life. It may help to distinguish those cases of FTLD with ubiquitin/TDP-43 pathology in their brains from those with tauopathy. As a predictive test, plasma TDP-43 level may have great practical value in directing therapeutic strategies aimed at preventing or removing tau or TDP-43 pathological changes from the brain in FTLD and AD.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 431 432 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 619 620 619 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 729 730 729 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 732 733 732 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 735 736 735 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 904 908 904 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGRN</italic>
###xml 911 912 911 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 914 915 914 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 917 918 917 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 920 921 920 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 923 925 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 1007 1011 1007 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAPT</italic>
###xml 1193 1194 1193 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1336 1337 1336 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 1399 1401 1399 1401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 1450 1452 1450 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 819 827 <span type="species:ncbi:9606">patients</span>
###xml 945 953 <span type="species:ncbi:9606">patients</span>
###xml 1296 1304 <span type="species:ncbi:9606">patients</span>
###xml 1365 1373 <span type="species:ncbi:9606">patients</span>
Recent research in neurodegenerative disease has highlighted the importance of a new molecular entity, the TAR DNA binding protein, TDP-43 (see [6] for review). Prior to the discovery in 2006 that TDP-43 was the target protein in the ubiquitinated cytoplasmic inclusions in neurones in certain histological forms of frontotemporal lobar degeneration (FTLD) known as FTLD-ubiquitinated (FTLD-U), and in motor neurone disease (MND) [2, 24], little was known of the function of this 414 amino acid nuclear protein beyond it serving a role in nuclear transcription in relationship to alternative splicing or exon skipping [5, 30] The involvement of TDP-43 in the ubiquitinated lesions of FTLD-U and MND has now been amply confirmed [6, 7, 9, 17, 29]. While ubiquitinated TDP-43 lesions are characteristically seen in those patients with inherited forms of FTLD associated with mutations in progranulin gene (PGRN) [3, 4, 8, 9, 16, 26, 28], in other patients with FTLD, such as those with mutations in tau gene (MAPT), or in those with a Pick body-type histology, where the underlying histology is based on the accumulation of aggregated tau proteins, no such TDP-43 pathological changes are seen [9]. Moreover, other studies have shown that TDP-43 pathological changes can also occur in about 20% of patients with Alzheimer's disease (AD) [1] and are widely present in patients with Lewy body diseases [21] or with parkinsonism-dementia complex of Guam [12].
###end p 4
###begin p 5
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 759 763 759 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAPT</italic>
###xml 767 771 767 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGRN</italic>
###xml 150 158 <span type="species:ncbi:9606">patients</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 731 739 <span type="species:ncbi:9606">patients</span>
Present data therefore suggest a widespread involvement of TDP-43 in neurodegenerative disease beyond FTLD-U and MND. In clinical terms, about 70% of patients with FTLD show behavioural and personality changes which are collectively described as frontotemporal dementia (FTD) [23]. Prospective and retrospective pathological studies have indicated that about half of all cases with FTD have a tau-positive, TDP-43-negative pathology, and half have ubiquitin-positive, TDP-43-positive pathology [10, 14, 15, 20, 27]. Nevertheless, in patients with FTLD, it is presently not possible to predict, in life, what the underlying histological changes might be solely on the basis of clinical phenotype, and it is only in that minority of patients where mutations in MAPT or PGRN are present that a tau or ubiquitin/TDP-43 based histology, respectively, can be confidently inferred.
###end p 5
###begin p 6
###xml 586 587 586 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 598 599 598 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 568 576 <span type="species:ncbi:9606">patients</span>
###xml 725 733 <span type="species:ncbi:9606">patients</span>
The differential diagnosis of dementia syndromes is clinical and radiological, and there are no litmus tests based on measures in blood or plasma to specify diagnosis. A biochemical marker that could distinguish between AD and FTLD, or between the histological subtypes of FTLD, would be not only of great diagnostic value, but would be highly pertinent to the future development of drugs aimed at preventing or removing the intraneuronal accumulation of tau or TDP-43 proteins in these degenerative disorders. Given the pathological observations that a proportion of patients with AD [1] or FTLD [9, 14, 15, 19, 27] harbour TDP-43 pathological changes within their brains, it can be hypothesised that similar proportions of patients might show altered blood or plasma levels of TDP-43, and that this could be a useful biomarker of the presence of TDP-43 brain pathology.
###end p 6
###begin p 7
###xml 771 775 771 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAPT</italic>
###xml 779 783 779 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGRN</italic>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
###xml 627 635 <span type="species:ncbi:9606">patients</span>
In this present study we have investigated whether TDP-43 can be detected in plasma in patients with FTD and AD, and in normal control subjects, by developing an ELISA-based assay. We show that not only can TDP-43 be detected in plasma, but more importantly, that the level of this is elevated in a proportion of each group of patients similar to that seen in patients with known TDP-43 brain pathology. Measurement of plasma TDP-43 may therefore have utility in evidencing the presence of brain TDP-43 based pathologies in neurodegenerative disease, and perhaps more importantly be capable of discriminating during life those patients with FTLD associated with ubiquitin/TDP-43 pathological changes in their brains from those with tauopathy, when a defining mutation in MAPT or PGRN is absent.
###end p 7
###begin title 8
Materials and methods
###end title 8
###begin title 9
Blood samples
###end title 9
###begin p 10
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 863 864 863 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 907 908 907 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1092 1094 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1346 1353 1346 1353 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1353 1463 1353 1463 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="11">Details of groups of patients with AD and FTD, and control subjects, at the time when blood samples were taken</p>
###xml 1353 1463 1353 1463 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="11">Details of groups of patients with AD and FTD, and control subjects, at the time when blood samples were taken</p></caption>
###xml 1463 1463 1463 1463 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1463 1470 1463 1470 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Control</th>
###xml 1470 1472 1470 1472 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</th>
###xml 1472 1475 1472 1475 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FTD</th>
###xml 1463 1475 1463 1475 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left">Control</th><th align="left">AD</th><th align="left">FTD</th></tr>
###xml 1463 1475 1463 1475 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left">Control</th><th align="left">AD</th><th align="left">FTD</th></tr></thead>
###xml 1485 1486 1485 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1475 1487 1475 1487 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Patients (<italic>n</italic>)</td>
###xml 1487 1489 1487 1489 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">85</td>
###xml 1489 1492 1489 1492 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">102</td>
###xml 1492 1494 1492 1494 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">35</td>
###xml 1475 1494 1475 1494 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Patients (<italic>n</italic>)</td><td align="left">85</td><td align="left">102</td><td align="left">35</td></tr>
###xml 1494 1511 1494 1511 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age range (years)</td>
###xml 1511 1516 1511 1516 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">42&#8211;83</td>
###xml 1516 1521 1516 1521 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">43&#8211;88</td>
###xml 1521 1526 1521 1526 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">42&#8211;78</td>
###xml 1494 1526 1494 1526 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Age range (years)</td><td align="left">42&#8211;83</td><td align="left">43&#8211;88</td><td align="left">42&#8211;78</td></tr>
###xml 1526 1549 1526 1547 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean age (years) &#177; SD</td>
###xml 1549 1561 1547 1557 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">71.3 &#177; 8.3</td>
###xml 1561 1573 1557 1567 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">64.2 &#177; 9.3</td>
###xml 1573 1585 1567 1577 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">62.4 &#177; 8.2</td>
###xml 1526 1585 1526 1577 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean age (years) &#177; SD</td><td align="left">71.3 &#177; 8.3</td><td align="left">64.2 &#177; 9.3</td><td align="left">62.4 &#177; 8.2</td></tr>
###xml 1585 1617 1577 1607 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean age of onset (years) &#177; SD</td>
###xml 1617 1620 1607 1610 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n/a</td>
###xml 1620 1632 1610 1620 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">61.5 &#177; 9.4</td>
###xml 1632 1644 1620 1630 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">69.7 &#177; 8.4</td>
###xml 1585 1644 1577 1630 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean age of onset (years) &#177; SD</td><td align="left">n/a</td><td align="left">61.5 &#177; 9.4</td><td align="left">69.7 &#177; 8.4</td></tr>
###xml 1644 1680 1630 1664 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean disease duration (years) &#177; SD</td>
###xml 1680 1683 1664 1667 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n/a</td>
###xml 1683 1694 1667 1676 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.9 &#177; 1.8</td>
###xml 1694 1705 1676 1685 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.7 &#177; 2.1</td>
###xml 1644 1705 1630 1685 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean disease duration (years) &#177; SD</td><td align="left">n/a</td><td align="left">2.9 &#177; 1.8</td><td align="left">2.7 &#177; 2.1</td></tr>
###xml 1727 1728 1707 1708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1705 1729 1685 1709 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gender: Male:Female% (<italic>n</italic>)</td>
###xml 1729 1746 1709 1726 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">43.5:56.5 (37:48)</td>
###xml 1746 1763 1726 1743 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">51.9:48.1 (53:49)</td>
###xml 1763 1780 1743 1760 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">48.6:51.4 (17:18)</td>
###xml 1705 1780 1685 1760 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Gender: Male:Female% (<italic>n</italic>)</td><td align="left">43.5:56.5 (37:48)</td><td align="left">51.9:48.1 (53:49)</td><td align="left">48.6:51.4 (17:18)</td></tr>
###xml 1780 1801 1760 1781 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean absorbance value</td>
###xml 1801 1805 1781 1785 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.02</td>
###xml 1805 1809 1785 1789 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.13</td>
###xml 1809 1813 1789 1793 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.26</td>
###xml 1780 1813 1760 1793 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean absorbance value</td><td align="left">0.02</td><td align="left">0.13</td><td align="left">0.26</td></tr>
###xml 1813 1836 1793 1816 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Median absorbance value</td>
###xml 1836 1841 1816 1821 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8722;0.04</td>
###xml 1841 1845 1821 1825 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.02</td>
###xml 1845 1849 1825 1829 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.11</td>
###xml 1813 1849 1793 1829 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Median absorbance value</td><td align="left">&#8722;0.04</td><td align="left">0.02</td><td align="left">0.11</td></tr>
###xml 1849 1902 1829 1882 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Percentage of samples over the 0.11 cut-off point (%)</td>
###xml 1902 1905 1882 1885 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8.8</td>
###xml 1905 1907 1885 1887 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">23</td>
###xml 1907 1909 1887 1889 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">46</td>
###xml 1849 1909 1829 1889 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Percentage of samples over the 0.11 cut-off point (%)</td><td align="left">8.8</td><td align="left">23</td><td align="left">46</td></tr>
###xml 1475 1909 1475 1889 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Patients (<italic>n</italic>)</td><td align="left">85</td><td align="left">102</td><td align="left">35</td></tr><tr><td align="left">Age range (years)</td><td align="left">42&#8211;83</td><td align="left">43&#8211;88</td><td align="left">42&#8211;78</td></tr><tr><td align="left">Mean age (years) &#177; SD</td><td align="left">71.3 &#177; 8.3</td><td align="left">64.2 &#177; 9.3</td><td align="left">62.4 &#177; 8.2</td></tr><tr><td align="left">Mean age of onset (years) &#177; SD</td><td align="left">n/a</td><td align="left">61.5 &#177; 9.4</td><td align="left">69.7 &#177; 8.4</td></tr><tr><td align="left">Mean disease duration (years) &#177; SD</td><td align="left">n/a</td><td align="left">2.9 &#177; 1.8</td><td align="left">2.7 &#177; 2.1</td></tr><tr><td align="left">Gender: Male:Female% (<italic>n</italic>)</td><td align="left">43.5:56.5 (37:48)</td><td align="left">51.9:48.1 (53:49)</td><td align="left">48.6:51.4 (17:18)</td></tr><tr><td align="left">Mean absorbance value</td><td align="left">0.02</td><td align="left">0.13</td><td align="left">0.26</td></tr><tr><td align="left">Median absorbance value</td><td align="left">&#8722;0.04</td><td align="left">0.02</td><td align="left">0.11</td></tr><tr><td align="left">Percentage of samples over the 0.11 cut-off point (%)</td><td align="left">8.8</td><td align="left">23</td><td align="left">46</td></tr></tbody>
###xml 1463 1909 1463 1889 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Control</th><th align="left">AD</th><th align="left">FTD</th></tr></thead><tbody><tr><td align="left">Patients (<italic>n</italic>)</td><td align="left">85</td><td align="left">102</td><td align="left">35</td></tr><tr><td align="left">Age range (years)</td><td align="left">42&#8211;83</td><td align="left">43&#8211;88</td><td align="left">42&#8211;78</td></tr><tr><td align="left">Mean age (years) &#177; SD</td><td align="left">71.3 &#177; 8.3</td><td align="left">64.2 &#177; 9.3</td><td align="left">62.4 &#177; 8.2</td></tr><tr><td align="left">Mean age of onset (years) &#177; SD</td><td align="left">n/a</td><td align="left">61.5 &#177; 9.4</td><td align="left">69.7 &#177; 8.4</td></tr><tr><td align="left">Mean disease duration (years) &#177; SD</td><td align="left">n/a</td><td align="left">2.9 &#177; 1.8</td><td align="left">2.7 &#177; 2.1</td></tr><tr><td align="left">Gender: Male:Female% (<italic>n</italic>)</td><td align="left">43.5:56.5 (37:48)</td><td align="left">51.9:48.1 (53:49)</td><td align="left">48.6:51.4 (17:18)</td></tr><tr><td align="left">Mean absorbance value</td><td align="left">0.02</td><td align="left">0.13</td><td align="left">0.26</td></tr><tr><td align="left">Median absorbance value</td><td align="left">&#8722;0.04</td><td align="left">0.02</td><td align="left">0.11</td></tr><tr><td align="left">Percentage of samples over the 0.11 cut-off point (%)</td><td align="left">8.8</td><td align="left">23</td><td align="left">46</td></tr></tbody></table>
###xml 1346 1909 1346 1889 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="11">Details of groups of patients with AD and FTD, and control subjects, at the time when blood samples were taken</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Control</th><th align="left">AD</th><th align="left">FTD</th></tr></thead><tbody><tr><td align="left">Patients (<italic>n</italic>)</td><td align="left">85</td><td align="left">102</td><td align="left">35</td></tr><tr><td align="left">Age range (years)</td><td align="left">42&#8211;83</td><td align="left">43&#8211;88</td><td align="left">42&#8211;78</td></tr><tr><td align="left">Mean age (years) &#177; SD</td><td align="left">71.3 &#177; 8.3</td><td align="left">64.2 &#177; 9.3</td><td align="left">62.4 &#177; 8.2</td></tr><tr><td align="left">Mean age of onset (years) &#177; SD</td><td align="left">n/a</td><td align="left">61.5 &#177; 9.4</td><td align="left">69.7 &#177; 8.4</td></tr><tr><td align="left">Mean disease duration (years) &#177; SD</td><td align="left">n/a</td><td align="left">2.9 &#177; 1.8</td><td align="left">2.7 &#177; 2.1</td></tr><tr><td align="left">Gender: Male:Female% (<italic>n</italic>)</td><td align="left">43.5:56.5 (37:48)</td><td align="left">51.9:48.1 (53:49)</td><td align="left">48.6:51.4 (17:18)</td></tr><tr><td align="left">Mean absorbance value</td><td align="left">0.02</td><td align="left">0.13</td><td align="left">0.26</td></tr><tr><td align="left">Median absorbance value</td><td align="left">&#8722;0.04</td><td align="left">0.02</td><td align="left">0.11</td></tr><tr><td align="left">Percentage of samples over the 0.11 cut-off point (%)</td><td align="left">8.8</td><td align="left">23</td><td align="left">46</td></tr></tbody></table></table-wrap>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 220 227 <span type="species:ncbi:9606">patient</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 525 533 <span type="species:ncbi:9606">Patients</span>
###xml 832 840 <span type="species:ncbi:9606">patients</span>
###xml 967 973 <span type="species:ncbi:9606">people</span>
###xml 1067 1075 <span type="species:ncbi:9606">patients</span>
###xml 1374 1382 <span type="species:ncbi:9606">patients</span>
Blood samples were obtained with Ethical permissions from 137 patients, 35 with FTD and 102 with AD, and 85 non-demented control subjects (Table 1). All patients with FTD and AD had been assessed (by DN, JSS) within out-patient clinics at the Cerebral Function Unit, Greater Manchester Neurosciences Centre. All patients had undergone historical interview in the presence of a family caregiver and comprehensive cognitive assessment to obtain information about the nature and progression of cognitive and functional decline. Patients with AD and FTD fulfilled the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD [18] and International criteria for FTD [22], respectively. Control subjects were either spouses of patients attending CFU clinic (n = 13), or a sample of healthy volunteers (n = 72) drawn randomly from a cohort of 767 mentally normal people aged >50 years, resident within the same Greater Manchester region from which the AD and FTD patients were recruited [25]. The latter comprised a longitudinal ageing study group who had been screened psychologically for absence of cognitive impairment consistent with dementia. All blood samples had been collected with the approval of the local ethics research committee.Table 1Details of groups of patients with AD and FTD, and control subjects, at the time when blood samples were takenControlADFTDPatients (n)8510235Age range (years)42-8343-8842-78Mean age (years) +/- SD71.3 +/- 8.364.2 +/- 9.362.4 +/- 8.2Mean age of onset (years) +/- SDn/a61.5 +/- 9.469.7 +/- 8.4Mean disease duration (years) +/- SDn/a2.9 +/- 1.82.7 +/- 2.1Gender: Male:Female% (n)43.5:56.5 (37:48)51.9:48.1 (53:49)48.6:51.4 (17:18)Mean absorbance value0.020.130.26Median absorbance value-0.040.020.11Percentage of samples over the 0.11 cut-off point (%)8.82346
###end p 10
###begin p 11
###xml 21 29 <span type="species:ncbi:9606">patients</span>
Details of groups of patients with AD and FTD, and control subjects, at the time when blood samples were taken
###end p 11
###begin p 12
Plasma was separated from whole blood samples (5 ml blood with EDTA acting as anti-coagulant) by routine methods, and stored in deep freeze (-80degreesC) until assay.
###end p 12
###begin title 13
Immunoassay protocol
###end title 13
###begin p 14
###xml 344 345 336 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1586 1587 1553 1554 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1589 1590 1556 1557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1655 1656 1622 1623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 912 918 <span type="species:ncbi:9986">rabbit</span>
###xml 1171 1175 <span type="species:ncbi:9925">goat</span>
###xml 1181 1187 <span type="species:ncbi:9986">rabbit</span>
###xml 1218 1229 <span type="species:ncbi:3704">horseradish</span>
An antibody-sandwich ELISA was developed to measure the TDP-43 concentration in plasma samples. The ELISA plates (96-well PVC assay plates, Iwaki, Japan) were coated by overnight incubation at 4degreesC with 0.2 mug/ml anti-TDP monoclonal antibody (H00023435-M01, clone 2E2-D3, Abnova Corporation, Taiwan), 100 mul/well, diluted in 200 mM NaHCO3 buffer, pH 9.6, containing 0.02% (w/v) sodium azide. The plates were washed 3 times with PBST (PBS (0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, pH 7.4) containing 0.05% Tween 20), and incubated with 200 mul/well of blocking buffer (PBS containing 2.5% gelatin and 0.05% Tween 20) for 2 h at 37degreesC. The plates were again washed 3 times with PBST, and 100 mul of the plasma samples to be tested, diluted 1:1 with PBS, were added to each of three wells. After washing 3 times with PBST, 100 mul of the detection antibody, TDP rabbit polyclonal antibody (BC001487, ProteinTech Group, Chicago) diluted to 0.2 mug/ml in blocking buffer, was added per well and the plates were incubated at 37degreesC for 2 h. After another wash (as before), the plates were incubated with 100 mul/well of goat anti-rabbit secondary antibody coupled to horseradish peroxidase (HRP) (Dako Ltd., Ely, U.K.), diluted 1:10,000 in blocking buffer, at 37degreesC for 1 h. The plates were then washed again with PBST, before adding 100 mul/well Sure Blue TMB Microwell Peroxidase Substrate (KPL Inc, Maryland, USA) and leaving the colour to develop for 30 min at room temperature. Finally, 100 mul/well of stop solution (0.3 M H2SO4) was added and absorbance values were read at 450 nm in a Victor2 multi-function microtitre plate reader. Net absorbance was calculated by deducting the mean value obtained for a triplicate of "blank" wells containing PBS only.
###end p 14
###begin p 15
The antibody-sandwich ELISA using polyclonal TDP-43 antibody (BC001487) as capture antibody was also successful and gave similar signals. However, the monoclonal antibody (2E2-D3) was chosen as the preferred capture antibody as background signals were smaller.
###end p 15
###begin p 16
Recombinant TDP-43 protein (MW 54.3 KDa) (AAH01487, 1 -261, Abnova Corporation, Taiwan, with 26 KDa GST tag) was used in the standard curve.
###end p 16
###begin title 17
Immunoprecipitation of TDP-43 from plasma
###end title 17
###begin p 18
###xml 79 85 <span type="species:ncbi:9986">rabbit</span>
Dynabeads covalently coupled with recombinant protein A, were derivatised with rabbit polyclonal anti-TDP-43 antibody (BC001487, ProteinTech Group, Chicago) as recommended by the manufacturer (Dynal Biotech LTD.,Wirral, UK). 300 mul plasma was added to the beads and incubated overnight at 4degreesC. The plasma samples were chosen according to the ELISA results, with one sample giving a high signal and the other a low signal. The beads were then washed three times with 0.1 M phosphate buffer, pH 8.2. Any captured TDP-43 was eluted from the beads by boiling for 10 min in NuPAGE LDS sample buffer (Invitrogen Ltd., UK) and examined by gel electrophoresis and immunoblotting.
###end p 18
###begin title 19
Gel electrophoresis and immunoblotting
###end title 19
###begin p 20
###xml 407 413 <span type="species:ncbi:9986">rabbit</span>
###xml 496 501 <span type="species:ncbi:10090">mouse</span>
###xml 701 705 <span type="species:ncbi:9925">goat</span>
###xml 711 717 <span type="species:ncbi:9986">rabbit</span>
###xml 721 725 <span type="species:ncbi:9925">goat</span>
###xml 731 736 <span type="species:ncbi:10090">mouse</span>
The protein eluted from the magnetic dynabeads (see above) was separated on NUPAGE Bis-Tris 4-12%, 1 mm gels (Invitrogen). The separated proteins were transferred to nitrocellulose membranes (0.45 mum, Invitrogen) at 30 V, 125 mA for 1 h. Membranes were blocked with 5% Marvel dried skimmed milk, dissolved in PBST for 1 h. The membranes were probed overnight at 4degreesC with either anti-TDP-43 antibody, rabbit polyclonal (BC001487, ProteinTech Group, Chicago) 1:1,000 in PBST, or anti-TDP-43 mouse monoclonal antibody (H00023435-M01, clone 2E2-D3, Abnova Corporation, Taiwan) 1:1,000 in PBST, as indicated. The membranes were washed three times in PBST, followed by incubation with HRP-conjugated goat anti-rabbit or goat anti-mouse (Dako LTD., Ely, U.K.), 1:10,000 in PBST, as appropriate, for 1 h. The protein bands were visualised using ECL reagents (Pierce, Rockford, IL) as described by the manufacturer.
###end p 20
###begin title 21
Statistical analyses
###end title 21
###begin p 22
###xml 75 83 <span type="species:ncbi:9606">patients</span>
All data were analysed using SPSS v 14.0. Because OD values for FTD and AD patients, as well as control subjects were not normally distributed according to Kolmogorov-Smirnov test, non-parametric Kruskal-Wallis test was used throughout to compare groups, with post hoc Mann-Whitney test being employed when the results of Kruskal-Wallis test yielded significant group differences.
###end p 22
###begin title 23
Results
###end title 23
###begin p 24
###xml 48 49 48 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 309 310 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 527 528 523 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 649 650 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 751 752 745 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 761 762 755 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 880 881 872 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 890 891 882 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 912 913 902 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 921 922 911 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 984 985 972 973 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 993 994 981 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1192 1193 1172 1173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1202 1203 1182 1183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1338 1339 1318 1319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1410 1411 1390 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1437 1443 1417 1423 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1443 1502 1423 1480 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25">Standard curve for the TDP-43 ELISA (data show mean &#177; SD)</p>
###xml 1443 1502 1423 1480 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="25">Standard curve for the TDP-43 ELISA (data show mean &#177; SD)</p></caption>
###xml 1502 1502 1480 1480 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_389_Fig1_HTML" id="MO1"/>
###xml 1437 1502 1417 1480 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="25">Standard curve for the TDP-43 ELISA (data show mean &#177; SD)</p></caption><graphic position="anchor" xlink:href="401_2008_389_Fig1_HTML" id="MO1"/></fig>
###xml 1502 1508 1480 1486 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1595 1598 1573 1576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">box</italic>
###xml 1662 1672 1640 1650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">solid line</italic>
###xml 1690 1693 1668 1671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">box</italic>
###xml 1710 1721 1688 1699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dashed line</italic>
###xml 1760 1764 1738 1742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dots</italic>
###xml 1770 1781 1748 1759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dotted line</italic>
###xml 1508 1879 1486 1857 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26">Box-whisker plots for the plasma ELISA results (absorbance values). The length of each <italic>box</italic> represents the interquartile range (75&#8211;25%) of the sample, the <italic>solid line</italic> drawn across the <italic>box</italic> the median, the <italic>dashed line</italic> the mean, and outliers are denoted by <italic>dots</italic>. The <italic>dotted line</italic> representing the 0.11 cut-off corresponds to the 99% upper confidence level for the control group</p>
###xml 1508 1879 1486 1857 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="26">Box-whisker plots for the plasma ELISA results (absorbance values). The length of each <italic>box</italic> represents the interquartile range (75&#8211;25%) of the sample, the <italic>solid line</italic> drawn across the <italic>box</italic> the median, the <italic>dashed line</italic> the mean, and outliers are denoted by <italic>dots</italic>. The <italic>dotted line</italic> representing the 0.11 cut-off corresponds to the 99% upper confidence level for the control group</p></caption>
###xml 1879 1879 1857 1857 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_389_Fig2_HTML" id="MO2"/>
###xml 1502 1879 1480 1857 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="26">Box-whisker plots for the plasma ELISA results (absorbance values). The length of each <italic>box</italic> represents the interquartile range (75&#8211;25%) of the sample, the <italic>solid line</italic> drawn across the <italic>box</italic> the median, the <italic>dashed line</italic> the mean, and outliers are denoted by <italic>dots</italic>. The <italic>dotted line</italic> representing the 0.11 cut-off corresponds to the 99% upper confidence level for the control group</p></caption><graphic position="anchor" xlink:href="401_2008_389_Fig2_HTML" id="MO2"/></fig>
###xml 506 514 <span type="species:ncbi:9606">patients</span>
###xml 561 569 <span type="species:ncbi:9606">patients</span>
###xml 591 599 <span type="species:ncbi:9606">patients</span>
###xml 606 614 <span type="species:ncbi:9606">patients</span>
###xml 671 679 <span type="species:ncbi:9606">patients</span>
###xml 795 803 <span type="species:ncbi:9606">patients</span>
###xml 1079 1087 <span type="species:ncbi:9606">patients</span>
A standard curve for the ELISA is shown in Fig. 1. The ELISA data from the plasma samples indicate that in control subjects, in most instances, TDP-43 was barely detectable (mean +/- SD, OD = 0.02 +/- 0.32), with just 8 individuals (8.8%) having absorbance (optical density or OD) values exceeding 0.11 (Fig. 2). This value corresponds to the 99% upper confidence level and was subsequently chosen to represent the 'cut off' point of 'normal' TDP-43 values. In AD, TDP-43 was again barely detectable in 79 patients (78%) (Fig. 2), though OD exceeded 0.11 in 23 patients (22%). In FTD, 16/35 patients (46%) patients had OD value exceeding 0.11 (Fig. 2). The proportion of patients with OD greater than 0.11 differed significantly across the groups (chi2 = 19.8; P < 0.001) with the proportion of patients with OD values greater than 0.11 being significantly higher in both FTD (chi2 = 20.4; P < 0.001) and AD (chi2 = 5.8; P = 0.016) compared to controls, and in FTD compared to AD (chi2 = 6.9; P = 0.009). Consequently, the mean OD values for control subjects (0.02 +/- 0.32) and patients with FTD (0.26 +/- 0.52) and AD (0.13 +/- 0.33) were significantly different by Kruskal-Wallis test (chi2 = 53.2; P < 0.001), with post hoc Mann-Whitney test showing mean values for both FTD and AD groups to be significantly different from controls (P < 0.001), with mean OD in FTD group also being significantly greater (P = 0.037) than that in AD.Fig. 1Standard curve for the TDP-43 ELISA (data show mean +/- SD)Fig. 2Box-whisker plots for the plasma ELISA results (absorbance values). The length of each box represents the interquartile range (75-25%) of the sample, the solid line drawn across the box the median, the dashed line the mean, and outliers are denoted by dots. The dotted line representing the 0.11 cut-off corresponds to the 99% upper confidence level for the control group
###end p 24
###begin p 25
Standard curve for the TDP-43 ELISA (data show mean +/- SD)
###end p 25
###begin p 26
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">box</italic>
###xml 154 164 154 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">solid line</italic>
###xml 182 185 182 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">box</italic>
###xml 202 213 202 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dashed line</italic>
###xml 252 256 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dots</italic>
###xml 262 273 262 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dotted line</italic>
Box-whisker plots for the plasma ELISA results (absorbance values). The length of each box represents the interquartile range (75-25%) of the sample, the solid line drawn across the box the median, the dashed line the mean, and outliers are denoted by dots. The dotted line representing the 0.11 cut-off corresponds to the 99% upper confidence level for the control group
###end p 26
###begin p 27
###xml 361 362 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 453 459 453 459 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 483 489 483 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 1</italic>
###xml 541 547 541 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 2</italic>
###xml 459 617 459 617 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28">Immunoblotting results. <italic>Lane 1</italic> molecular weight markers (numbers to left in kDa); <italic>lane 2</italic> protein immunocaptured from a plasma sample with a high ELISA reading</p>
###xml 459 617 459 617 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28">Immunoblotting results. <italic>Lane 1</italic> molecular weight markers (numbers to left in kDa); <italic>lane 2</italic> protein immunocaptured from a plasma sample with a high ELISA reading</p></caption>
###xml 617 617 617 617 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_389_Fig3_HTML" id="MO3"/>
###xml 453 617 453 617 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="28">Immunoblotting results. <italic>Lane 1</italic> molecular weight markers (numbers to left in kDa); <italic>lane 2</italic> protein immunocaptured from a plasma sample with a high ELISA reading</p></caption><graphic position="anchor" xlink:href="401_2008_389_Fig3_HTML" id="MO3"/></fig>
###xml 155 161 <span type="species:ncbi:9986">rabbit</span>
When protein from plasma samples with high levels of TDP-43 (based on ELISA results) was immunocaptured with magnetic Dynabeads coupled to the anti-TDP-43 rabbit polyclonal antibody, and then examined by gel electrophoresis and western blotting employing the anti-TDP-43 monoclonal antibody for detection, only a single band migrating at ~43 kDa was seen (Fig. 3, lane 2). No specific bands were detected in similarly treated low-reading plasma samples.Fig. 3Immunoblotting results. Lane 1 molecular weight markers (numbers to left in kDa); lane 2 protein immunocaptured from a plasma sample with a high ELISA reading
###end p 27
###begin p 28
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 1</italic>
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 2</italic>
Immunoblotting results. Lane 1 molecular weight markers (numbers to left in kDa); lane 2 protein immunocaptured from a plasma sample with a high ELISA reading
###end p 28
###begin p 29
There were no significant correlations between plasma TDP-43 level and age at onset of illness, or duration of illness up to time of sampling, for AD and FTD groups, either when the whole AD or FTD group, or just those individuals with high TDP-43 levels, were considered.
###end p 29
###begin title 30
Discussion
###end title 30
###begin p 31
###xml 923 924 923 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 926 928 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 144 150 <span type="species:ncbi:9606">people</span>
###xml 352 358 <span type="species:ncbi:9606">people</span>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
In the present study we have shown for the first time that the TAR DNA-binding protein, TDP-43, can be detected within plasma of normal control people, as well as individuals with neurodegenerative diseases such as AD and FTD. The ELISA data indicate that TDP-43 is present at extremely low concentrations, or is absent, in the vast majority of normal people, and in AD or FTD there are substantial numbers of patients in whom TDP-43 is likewise barely present. However, group comparisons by ELISA reveal a highly significant increase (approximately 13-fold) in mean TDP-43 absorbance levels in FTD compared to controls, whereas in AD the mean TDP-43 absorbance level was about 7-fold increased. The validity of the ELISA method is supported by the immunoblotting results. In accord with the ELISA data, an immunoreactive band migrating at 43 kDa, which corresponds precisely to the molecular weight of full-length TDP-43 [2, 24] was detected only in the high-reading plasma sample and not in the low-reading sample. This result not only confirms the specificity of the antibody pair employed for the sandwich ELISA, but also shows that the readout from the ELISA accurately reflects the levels of TDP-43 present in plasma.
###end p 31
###begin p 32
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 567 568 567 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 570 571 570 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 573 574 573 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 816 817 816 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 207 215 <span type="species:ncbi:9606">patients</span>
###xml 432 440 <span type="species:ncbi:9606">patients</span>
###xml 597 605 <span type="species:ncbi:9606">patients</span>
###xml 778 786 <span type="species:ncbi:9606">patients</span>
###xml 1000 1008 <span type="species:ncbi:9606">patients</span>
###xml 1052 1060 <span type="species:ncbi:9606">patients</span>
###xml 1111 1119 <span type="species:ncbi:9606">patients</span>
From histological studies, it is known that about 50% of patients with FTD have ubiquitin/TDP-43-based histology [6, 7, 10, 14, 15, 20, 27] and consequently it might be expected that a similar proportion of patients with this kind of pathology would be included within the present unselected FTD study group. In the present FTD cohort, there was a highly significant mean increase in plasma TDP-43 absorbance levels, with about 46% patients showing 'high' TDP-43 levels (ie above OD of 0.11 corresponding to 99% upper control limit). On the basis of autopsy studies [6, 7, 9] such a proportion of patients would have been anticipated if the presence of TDP-43 in plasma is indeed indexing the presence of TDP-43 pathology in brain. Likewise, in AD it is known that about 20-25% patients have TDP-43-based pathology [1] and again it might be anticipated that within the present group of unselected AD cases, a similar proportion of cases with TDP-43 pathology would exist. In the present AD group 22% patients showed 'high' TDP-43 values, while in most patients no increase was seen. Therefore the proportion of patients showing high plasma TDP-43 levels in both FTD and AD closely match, at least in numerical terms, those proportions that would be predicted to occur from histological studies.
###end p 32
###begin p 33
###xml 634 636 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
The few elderly control subjects with high TDP-43 levels (8%) may be patients with incipient neurodegenerative disease, most likely AD, since it has long been known that a very high proportion of mentally normal elderly subjects show at autopsy some degree of Alzheimer-type pathological changes in their brains (ie senile plaques and neurofibrillary tangles), and this may, as in AD itself, include some individuals with additional TDP-43 pathology. Indeed, the proportion of control subjects showing raised plasma TDP-43 levels recorded here is similar to the prevalence rate of elderly individuals with mild cognitive impairment. [11, 13, 19], supporting the view that such individuals might represent cases of early or incipient AD with additional TDP-43 pathological changes.
###end p 33
###begin p 34
###xml 1042 1046 1042 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAPT</italic>
###xml 1050 1054 1050 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGRN</italic>
###xml 1129 1133 1129 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAPT</italic>
###xml 1215 1216 1215 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1238 1242 1238 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGRN</italic>
###xml 1296 1297 1296 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1299 1300 1299 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1302 1303 1302 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1305 1306 1305 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1308 1310 1308 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1312 1314 1312 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 1316 1318 1316 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 1367 1371 1367 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAPT</italic>
###xml 1443 1447 1443 1447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGRN</italic>
###xml 1587 1591 1587 1591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGRN</italic>
###xml 1665 1669 1665 1669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAPT</italic>
###xml 1824 1828 1824 1828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAPT</italic>
###xml 1833 1837 1833 1837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGRN</italic>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 695 703 <span type="species:ncbi:9606">patients</span>
###xml 787 795 <span type="species:ncbi:9606">patients</span>
###xml 1025 1033 <span type="species:ncbi:9606">patients</span>
###xml 1115 1123 <span type="species:ncbi:9606">patients</span>
###xml 1353 1361 <span type="species:ncbi:9606">patients</span>
###xml 1549 1557 <span type="species:ncbi:9606">patients</span>
###xml 2016 2024 <span type="species:ncbi:9606">patients</span>
###xml 2188 2196 <span type="species:ncbi:9606">patients</span>
Although the numerical similarities between the proportions of patients with FTD and AD showing 'high' TDP-43 plasma levels and those displaying TDP-43 pathological changes at autopsy argue that measurement of plasma TDP-43 level can index the presence of TDP-43 pathology within the brain of patients with FTD or AD, we accept that these numerical associations may simply be fortuitous, or may reflect, for example, a compromised blood-brain barrier in FTD and AD, and recognise that the data we have presented here, although intriguing, is still very much preliminary. Present data, and the arguments we have presented based on this data, would be greatly strengthened if autopsy follow-up of patients with AD or FTD with high plasma TDP-43 values were available. However, because the patients investigated here were still in the early or middle stages of their illness when blood samples were taken, this will not be possible for many years to come. An alternative approach would be to compare plasma TDP-43 levels in FTD patients bearing MAPT or PGRN mutations, since it is known from histological studies that patients with MAPT mutations and tauopathy do not show TDP-43 pathological changes in their brains [9], whereas those with PGRN mutation always display TDP-43 pathological changes [3, 4, 8, 9, 16, 26, 28]. Hence, by the present argument, patients with MAPT mutations should show low (normal) plasma TDP-43 levels and those with PGRN mutations should show high(er) plasma TDP-43 levels. Unfortunately, within the present cohort of FTD patients there was only one bearer of PGRN mutation (in whom the plasma TDP-43 level was raised), and no bearers of MAPT mutation, so at present we are not realistically able to address this issue. We are presently aiming to collect further plasma samples from the surviving MAPT and PGRN mutation bearers within our FTD cohort. Until then, present data suggest, but do not definitively show, that measurement of plasma TDP-43 level might discriminate in life, those patients with FTD or AD with TDP-43 pathology from those without TDP-43 pathology (ie those with tau-based histological changes), even if it does not differentiate between patients with AD or FTD per se.
###end p 34
###begin p 35
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
Because all patients investigated were (when sampled) in early to middle stages of disease it has not been possible so far to follow or deduce how changes in plasma TDP-43 levels might change with disease progression or disease severity. Further studies based on repeat sampling from patients with elevated plasma TDP-43 levels will address this matter.
###end p 35
###begin p 36
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
Although we do not know the biological or functional significance of (the additional) TDP-43 pathology in patients with AD, as with FTD, there may be heuristic (future) management or therapeutic values in being able to predict the presence of TDP-43 changes in such patients. Given the possibility of tau- or TDP-43-based therapies becoming available for patients with AD or FTD, knowing who in AD or FTD is potentially able to benefit from tau and/or TDP-43 based therapy, according to predictive knowledge of underlying histology, would be of considerable practical value.
###end p 36
###begin p 37
Penelope Foulds was supported by a Studentship from Lancaster University. Dr. Pickering-Brown is the recipient of a Medical Research Council (MRC) New Investigator Award, and he and Professor Mann receive other funding from MRC, Alzheimer's Research Trust and the Motor Neurone Disease Association.
###end p 37
###begin p 38
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 38
###begin title 39
References
###end title 39
###begin article-title 40
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
###end article-title 40
###begin article-title 41
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
###end article-title 41
###begin article-title 42
Mutations in Progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
###end article-title 42
###begin article-title 43
Frontotemporal dementia and parkinsonism associated with the IVS1 + 1G --> A mutation in progranulin: a clinicopathologic study
###end article-title 43
###begin article-title 44
Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance
###end article-title 44
###begin article-title 45
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration
###end article-title 45
###begin article-title 46
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions
###end article-title 46
###begin article-title 47
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21
###end article-title 47
###begin article-title 48
Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43
###end article-title 48
###begin article-title 49
Frontotemporal dementia: clinicopathological correlations
###end article-title 49
###begin article-title 50
Mild cognitive impairment, amnestic type: an epidemiologic study
###end article-title 50
###begin article-title 51
TDP-43 is deposited in the Guam parkinsonism-dementia complex brains
###end article-title 51
###begin article-title 52
Prevalence of mild cognitive impairment: a population-based study in elderly subjects
###end article-title 52
###begin article-title 53
Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration
###end article-title 53
###begin article-title 54
Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration
###end article-title 54
###begin article-title 55
The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene
###end article-title 55
###begin article-title 56
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from Amyotrophic lateral sclerosis with SOD1 mutations
###end article-title 56
###begin article-title 57
###xml 128 133 <span type="species:ncbi:9606">Human</span>
Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease
###end article-title 57
###begin article-title 58
Prevalence and cognitive performances of clinical dementia rating 0.5 and mild cognitive impairment in Japan. The Tajiri project
###end article-title 58
###begin article-title 59
Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias
###end article-title 59
###begin article-title 60
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases
###end article-title 60
###begin article-title 61
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
###end article-title 61
###begin article-title 62
Frontotemporal dementia
###end article-title 62
###begin article-title 63
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
###end article-title 63
###begin article-title 64
Cathepsin D exon 2 polymorphism associated with general intelligence in a healthy older population
###end article-title 64
###begin article-title 65
Mutations in progranulin explain atypical phenotypes with variants in MAPT
###end article-title 65
###begin article-title 66
Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation
###end article-title 66
###begin article-title 67
Progranulin gene mutations associated with frontotemporal dementia and progressive aphasia
###end article-title 67
###begin article-title 68
TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation
###end article-title 68
###begin article-title 69
Structural diversity and functional implications of the eukaryotic TDP gene family
###end article-title 69
###begin p 70
P. Foulds and E. McAuley contributed equally to the study.
###end p 70

